Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 193

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 193
---
 Kineta’s product candidates, including:

| • |     | Kineta may be unable to generate sufficient preclinical, toxicology or other in vivo or in vitro data to obtain regulatory authorizations to commence a clinical trial; |

113

| • |     | Kineta may experience issues in reaching a consensus with regulatory authorities on trial design; |

| • |     | regulators or IRBs or ECs may not authorize Kineta or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; |

| • |     | Kineta may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; |

| • |     | clinical trial sites may deviate from a trial protocol or drop out of a trial or fail to conduct the trial in accordance with regulatory requirements; |

| • |     | the number of subjects required for clinical trials of Kineta’s product candidates may be larger than Kineta anticipates or subjects may fail to enroll or remain in clinical trials at the rate Kineta expects; |

| • |     | subjects that enroll in Kineta’s studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the subject from the trial, increase the needed enrollment size for the clinical trial or extend its duration; |

| • |     | subjects may choose an alternative treatment for the indication for which Kineta is developing its product candidates, or participate in competing clinical trials; |

| • |     | subjects may experience severe or unexpected drug-related adverse effects; |

| • |     | clinical trials of Kineta’s product candidates may produce unfavorable, inconclusive or clinically insignificant results; |

| • |     | Kineta may decide to, or regulators or IRBs or ECs may require Kineta to, make changes to a clinical trial protocol or conduct additional preclinical studies or clinical trials, or Kineta may decide to abandon product development programs; |

| • |     | Kineta may need to add new or additional clinical trial sites; |

| • |     | Kineta’s third-party contractors, including those manufacturing its product candidates or conducting clinical trials on its behalf, may fail to comply with regulatory requirements or meet their contractual obligations to Kineta in a timely manner, or at all; |

| • |     | Kineta may experience manufacturing delays, and any changes